High-altitude retinopathy (HAR) has traditionally been described by the fundus changes that appear after ascent to altitude. A new review argues that this definition misses the core biological problem that makes the condition worth studying: hypobaric hypoxia places simultaneous stress on two separate ocular circulations, on a metabolically demanding neural tissue, and on the blood–retinal barrier that maintains fluid balance in the eye.
Writing in Frontiers in Cell and Developmental Biology, a team from Chengdu University of Traditional Chinese Medicine proposes that the high-altitude retinal response is better understood as an adaptation–mismatch–decompensation spectrum rather than a linear cascade running from hypoxia to cell death. Depending on where a person sits on that spectrum, the response may remain a reversible vascular adjustment, or it may progress to hemorrhage, macular injury, and visual dysfunction.
A central claim of the review is that vascular and neural responses to altitude can diverge. Drawing on optical coherence tomography angiography (OCTA), functional OCT, and electroretinography (ERG), the authors note that perfusion-related compensation may persist even while retinal function declines, and that the two components may recover on different time scales after reoxygenation. This dissociation means that a normal-looking vascular picture does not guarantee normal retinal function, and it underlines why multimodal assessment is needed.
To sharpen the terminology, the review draws an explicit line between physiological adaptation and pathological disease. Reversible vascular or metabolic adjustment without barrier failure, structural injury, or persistent functional loss is termed physiological adaptation. The term high-altitude retinopathy is reserved for pathological retinal findings that can be attributed to altitude.
The review examines HAR at three linked levels: clinical differential diagnosis, the retinal neurovascular unit, and the potential therapeutic relevance of natural compounds and extracts. Within the neurovascular unit framework, the authors distinguish reversible vascular adjustment from neurovascular mismatch, blood–retinal barrier failure, and regulated cell death, positioning these as successive stages of decompensation rather than a single uniform process.
On treatment, the authors are deliberately cautious. They summarize current medical management without extrapolating general altitude-illness drugs to unproven retinal indications. In other words, a drug used for acute mountain sickness cannot simply be assumed to protect the retina; retinal safety and efficacy require their own evidence.
The therapeutic section applies a defined evidence hierarchy to chemically characterized natural compounds and extracts. Three have direct high-altitude retinal data: salidroside, derived from a well-characterized Rhodiola tangutica extract, along with resveratrol and hesperidin. Crucially, the authors emphasize that even this direct evidence remains preclinical. None of these compounds has been shown to prevent or treat retinopathy in humans at altitude.
Broader mechanistic insight comes from studies in other retinal hypoxia and ischemia models, which point to pathways involving mitochondrial quality control, ferroptosis, NLRP3 signaling, endothelial junctions, and glial metabolism. The review is explicit that these findings do not establish efficacy in HAR; they generate hypotheses about mechanism that would need to be tested in altitude-specific settings.
The authors close with a research agenda. Progress, they argue, will require longitudinal multimodal human phenotyping, standardized hypobaric models, retinal pharmacokinetics, causal target engagement, and clinical trials designed around exposure, susceptibility, and recovery. Until such work is done, the review’s contribution is conceptual: reframing HAR as a spectrum that separates adaptation from decompensation, and setting a rigorous evidentiary bar for any future retinal therapy.
Subject of Research: Neurovascular mechanisms of high-altitude retinopathy and the preclinical evidence for natural compounds
Article Title: Neurovascular mechanisms of high-altitude retinopathy and the potential therapeutic relevance of natural compounds
Article References: Yue, S., Shi, R., He, Y., Huang, J., Leng, X., Wu, Y., Huang, J., Zhang, M., & Lu, X. (2026). Neurovascular mechanisms of high-altitude retinopathy and the potential therapeutic relevance of natural compounds. Frontiers in Cell and Developmental Biology, 14, 2001737. https://doi.org/10.3389/fcell.2026.2001737
Image Credits: AI Generated
DOI: 10.3389/fcell.2026.2001737
Keywords: high-altitude retinopathy, hypobaric hypoxia, blood-retinal barrier, OCTA, electroretinography, retinal neurovascular unit, salidroside, resveratrol, hesperidin, ferroptosis, NLRP3 signaling, natural products
News Source: Cassandra Pierce. (October 28, 2026). Rethinking High-Altitude Retinopathy as a Spectrum of Vascular and Neural Responses. Scienmag.
